Drug Profile
RG 7212
Alternative Names: Anti-TWEAK MAb - Roche; Anti-TWEAK monoclonal antibody - Roche; RG-7212; RO-5458640Latest Information Update: 03 Feb 2014
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action TNFSF12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 30 Jan 2014 Discontinued - Phase-I for Solid tumours in Canada, Denmark and the Netherlands (IV)
- 01 Mar 2013 Roche completes a phase I multiple-ascending dose trial in Solid tumours (late stage disease) in Canada, Denmark and the Netherlands (NCT01383733)
- 01 Jul 2011 Phase-I clinical trials in Solid tumours in Canada (IV)